Articles tagged with Drug Studies
A new study published in the journal Brain found that patients with Parkinson's disease who experience tremor symptoms do not benefit from dopaminergic medication on their learning abilities. In contrast, patients without tremor show improvement in reward learning and faster deterioration of cognitive abilities.
Researchers found that tocotrienols extracted from palm oil activate Nrf2 nuclear translocation and increase the antioxidant-related hepatoprotective mechanism in mice liver cells. The study also showed that the effect is dose-dependent and functionally relevant.
A two-drug combination of dapagliflozin and exenatide continues to effectively control patients' glucose levels without losing efficacy over a two-year period. The study also revealed significant improvements in blood pressure and weight, contributing to overall health.
Researchers from Florida Atlantic University argue that remdesivir is justified for compassionate use in severely ill patients with COVID-19 due to its potential benefits in reducing recovery time. Despite FDA approval, the current evidence base supports the use of other proven preventive strategies such as social distancing and masking.
A new study examines clinical trials involving radiation therapy from 1996 to 2019 and finds that Black and Asian American patients are underrepresented, with 12% and 3% of trial participants respectively. The findings highlight the need for better inclusion of racial minorities in research studies.
Researchers have improved consistency assessment in meta-analysis by considering statistical power. This new measure can alter the interpretation of meta-analyses. Studies with high statistical power should have stronger effects on results.
A randomized trial will evaluate a telehealth-delivered collaborative care model to motivate primary care patients with opioid dependence and depression to increase engagement in evidence-based treatments. The study aims to improve depression symptoms and provide pragmatic clinical approaches to address this unmet challenge.
Researchers will present on anti-amyloid treatments and new late-stage clinical trials for Alzheimer's. NIA is funding over 230 active clinical trials to support the development of new treatments.
A double-blind clinical trial investigates the effectiveness of ondansetron, a cancer anti-sickness drug, in alleviating hallucinations in people with Parkinson's. The study aims to find new treatments for this challenging symptom, which affects 75% of UK Parkinson's patients.
Adagrasib achieves objective responses in nearly half of patients with non-small cell lung cancer; encouraging early results are seen in patients with colorectal, pancreatic, and endometrial cancer. The agent targets KRAS G12C mutation, leading to manageable side effects.
A clinical trial published in the New England Journal of Medicine shows that finerenone significantly slows the progression of diabetic kidney disease by 18% compared to a placebo. The study also found a reduction in cardiovascular event rates, offering new treatment options for patients with chronic kidney disease and type 2 diabetes.
A clinical trial called REPAIR-MDS will test repurposed drugs to improve hematological responses in MDS, reducing or reversing life-limiting deficiencies in red blood cells. The trial aims to improve the outlook for people with this rare condition, which has limited treatment options.
A new patient-reported outcome measure, SONG-HD Fatigue, has been validated to assess fatigue in patients receiving long-term dialysis treatments. The instrument calculates average fatigue over a period of 1 week, gauging tiredness, energy, and impact on life participation.
A new study found that malaria-preventive drugs can dramatically reduce infections in school children by half, leading to improved learning and reduced anemia. The analysis included 15,000 schoolchildren across seven African countries and showed a significant association between preventive treatment and better health outcomes.
A new study at Boston Medical Center found that the common treatment bevacizumab for diabetic macular edema is less effective for Black patients compared to white and Hispanic individuals. This disparity underscores the importance of increasing diversity in clinical trials to develop treatments tailored to all patient groups.
Two new UT Southwestern studies report that only half of practicing physicians are registered to vote, with time being the most common barrier faced by resident physicians. The researchers say finding ways to increase voter participation among doctors is critical as the nation tackles healthcare issues.
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) has achieved significant milestones in its first year, thanks to data sharing and collaboration among stakeholders. The platform serves as a centralized infrastructure to support data analysis and aid in the understanding of rare diseases.
A new study published in the New England Journal of Medicine found that tocilizumab does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19. The treatment was tested on 243 patients with high levels of inflammation and pneumonia, fever, or low ...
The VOYAGER PAD trial found that drug-coated devices do not increase mortality risk in patients with peripheral artery disease. Rivaroxaban use consistently reduced ischemic limb and cardiovascular outcomes regardless of device type.
A randomized trial comparing a nano-coated coronary stent with shorter dual anti-platelet therapy (DAPT) to a drug-eluting stent (DES) with guideline-recommended DAPT duration found no reduction in bleeding or thrombotic events. The study included 996 patients and found the rate of bleeding in the test group was 7.5% compared to 8.9% i...
The OPTIMIZE trial found that the new stent did not meet non-inferiority criteria due to high TVMI rates from high-sensitivity troponin biomarkers. However, independent analyses demonstrate non-inferiority with comparable relative non-inferiority margin, suggesting potential for improved clinical outcomes
The FORECAST trial found that fractional flow reserve derived from computed tomography coronary angiography (FFRCT) reduced the use of invasive coronary angiography by 22% without significantly reducing costs. The strategy also showed promise in terms of reducing healthcare utilization and improving patient outcomes.
A recent clinical trial found that patients with ALS who received the investigational neuroprotective therapy AMX0035 lived for a median of 6.5 months longer than those who received placebo. This result demonstrates the potential to prolong patient survival and slow disease progression.
A minimum unit price for alcohol policy significantly decreases deaths and hospitalizations related to alcohol use, according to a new report. By setting a floor price for alcohol sales, such policies help prevent the sale of cheap drinks with high alcohol content.
The 38th Annual Meeting of The Obesity Society will present innovative scientific research results through oral and poster abstracts. These communications highlight new anti-obesity medication clinical trials and comparisons of weight loss diets.
A new study found that 90% of CBD users claimed to use it for medical conditions such as autism, depression, and sleep disorders. In contrast, only 30% cited wellness benefits. The study highlights the need for enhanced regulation of the CBD market to prevent patients from forgoing proven treatments.
Aetion co-authored a study analyzing lethal coronaviruses SARS-CoV-2, SARS-CoV-1, and MERS-CoV to identify molecular characteristics of potential treatments. The study applied real-world data from COVID-19 patients to evaluate molecular hypotheses.
Researchers found that hypochlorous acid can chemically modify malodorous compounds and rapidly inactivate infectious particles, promoting greater latrine use. The study also shows potential for HOCl to improve latrine odor and reduce transmission of diseases such as dengue fever.
A review of 39 randomized clinical trials found that combining therapy with medication is more effective in preventing illness recurrence in people with bipolar disorder. Psychoeducation and group therapy were particularly helpful in reducing symptoms and improving outcomes.
A MU researcher developed a world's first health care transition readiness assessment for adolescents with autism, identifying skills needed for transition from pediatric care to adult care. The study found that young adults with autism can benefit from better understanding medication management, insurance policies and health care fina...
The NCI-MATCH trial, the largest precision medicine cancer trial to date, has made significant contributions to the use of tumor gene testing in selecting treatment for patients. The study found that nearly 40% of patients have matching tumor gene defects for targeted treatments.
The NIH has launched the ACTIV-5 Big Effect Trial to determine whether certain approved therapies or investigational drugs show promise against COVID-19. The study will enroll adult volunteers hospitalized with COVID-19 at up to 40 US sites and test three investigational treatments against a placebo.
Researchers found that older adults with heart failure are frequently prescribed 10 or more medications upon hospital discharge, leading to potential adverse effects. The study highlights the need for improved medication review processes to balance treatment benefits and risks.
Two studies from UC San Diego found that standing and light physical activity significantly reduce the risk of death, even for just 30 minutes a day. The research team also compared sedentary time in Americans to farmers in Malawi, finding substantially higher levels of activity among the latter group.
The study aims to examine the effectiveness of combining antiviral remdesivir with a highly concentrated solution of antibodies that neutralize SARS-CoV-2. The treatment is being tested in hospitalized adults with COVID-19 in various countries, with the goal of reducing the risk of serious illness and death.
The FDA has issued guidance on clinical trials for cancer drug development during the COVID-19 pandemic. The guidance highlights regulatory challenges and lessons learned from recent experiences. By providing this support, the FDA aims to facilitate oncology drug development in a challenging environment.
Researchers found that antibiotics were not worse than surgery in terms of overall health status, allowing most people to avoid operations. Patients treated with antibiotics often returned home faster but missed less time from work and school.
Researchers aim to develop treatments that can prevent or treat Alzheimer's disease with two large-scale studies on pre-dementia conditions MCR and brain stimulation techniques.
The CODA Trial found that antibiotics were not worse than surgery in measuring overall health status, allowing most people to avoid operations in the short term. Patients treated with antibiotics more often returned to the emergency department but missed less time from work and school.
Researchers at the University of Pittsburgh School of Medicine have developed a blood-clotting agent that can improve survival rates for severely injured trauma patients. The drug, tranexamic acid, was found to be safe and beneficial in certain subgroups of patients who received it early.
The CODA trial found that antibiotics can avoid surgery for more than 70% of patients with appendicitis. However, patients with an appendicolith may face higher complications and a greater risk of needing surgery.
A randomized controlled trial found that lopinavir-ritonavir treatment does not reduce deaths, hospital stay length, or ventilator risk for patients hospitalized with COVID-19. The RECOVERY trial's results support the update of clinical guidelines.
A study published in Nature Communications finds that a multiple sclerosis treatment inhibits coronavirus replication and reduces inflammation in human lung cells. Researchers are optimistic about the potential of dimethyl fumarate to combat COVID-19.
A new investigation by Science reveals that the FDA's enforcement of clinical trial regulations is often light-handed, slow-moving, and secretive. The agency rarely levels sanctions or disqualifies scientists from clinical research, and cases are frequently resolved based on unverified claims.
Scientists create drug-like compounds that bind and destroy COVID-19's frameshifting element to stop the virus from replicating. The findings demonstrate the feasibility of directly targeting viral RNA with small-molecule drugs.
A clinical trial found that a daily regimen of hydroxychloroquine did not reduce infection rates among healthcare workers. The study suggests that other prevention measures such as social distancing and vaccination may be more effective in preventing COVID-19.
A new study will explore the effectiveness of adalimumab as a treatment for patients with COVID-19 in community care settings, particularly in care homes. The trial aims to determine whether anti-TNF drugs can reduce disease progression and mortality in patients with severe symptoms.
Researchers developed AwareDX, a machine learning algorithm that groups data into sex-balanced subsets to identify potential sex-specific drug effects. The algorithm has successfully predicted effects for several drugs, including simvastatin and risperidone, based on genetic differences between men and women.
A study found that FDA evaluations for new opioid drugs approved between 1997 and 2018 lacked systematic assessments of safety-related outcomes, particularly for chronic pain applications. The analysis revealed that trials often excluded patients who could not tolerate the drugs and failed to assess important adverse events.
Researchers at MUSC are using new technologies to conduct remote smoking cessation clinical trials, reaching smokers in rural areas and beyond. With electronic consent and smartphone-enabled devices, participants can complete trials from home, providing more representative data.
Two newer diabetes medications can significantly reduce the risk of heart disease, cardiovascular events, and end-stage kidney disease. They also lower blood pressure and slow chronic kidney disease progression.
Researchers at University of Minnesota Medical School have received seed funding for a clinical study investigating the use of metformin as a COVID-19 treatment and prevention method. The team aims to definitively study whether or not metformin prevents SARS-CoV-2 infection and severe COVID-19 disease, with potential benefits of reduci...
A new drug, vamorolone, has shown promise in reducing side effects associated with current steroid treatments for Duchenne muscular dystrophy. Interim results from a 24-month clinical trial suggest that vamorolone may retain or improve the therapeutic benefits of steroids while minimizing risks.
A new study aims to replace daily eye drops with a brief low-energy laser procedure to lower eye pressure in glaucoma patients. The trial seeks to improve patients' quality of life and potentially offer a 'drop-free lifetime.'
A recent clinical trial found that ertugliflozin demonstrated non-inferiority on the rate of cardiovascular death, heart attack or stroke compared to placebo. The study results add to growing evidence supporting guidelines for using SGLT2 inhibitors to prevent adverse cardiovascular outcomes in type 2 diabetes patients.
A fourth Phase 3 clinical trial has begun enrolling adult volunteers to evaluate the investigational Janssen COVID-19 vaccine. The trial aims to assess the vaccine's ability to prevent symptomatic COVID-19 after a single dose regimen.
A six-year study found metformin slowed cognitive decline and reduced dementia risk in individuals with type 2 diabetes. Researchers believe the medication may also benefit those at risk of cognitive decline without diabetes. The study suggests a potential repurposing of metformin to prevent cognitive decline in older people.
A Canadian study found that SGLT2 inhibitors reduce the risk of cardiovascular events, including heart attack and stroke, among patients with type 2 diabetes. The study's findings suggest that these drugs offer cardioprotective benefits in a real-world setting.
Researchers at Medical University of South Carolina found that genetic variation in three specific brain genes can predict the effectiveness of naltrexone in treating alcohol use disorder. Patients with certain combinations of gene variations showed consistently reduced drinking when taking naltrexone, making personalized medicine a po...
A new Mayo Clinic study found that clinical oncologists are less informed about the federal Right to Try (RTT) law, citing concerns over patient safety and regulatory burden. The study also revealed that most oncologists had limited familiarity with RTT despite having experience with FDA's Expanded Access Programs.